Daudi (ATCC® CCL-213)

Organism: Homo sapiens, human  /  Tissue: peripheral blood  /  Cell Type: B lymphoblast

Organism Homo sapiens, human
Tissue
peripheral blood
Cell Type B lymphoblast
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2 Cells Contain HERPESVIRUS
Disease Burkitt's lymphoma
Age 16 years
Gender male
Ethnicity Black
Applications
The Daudi is a well characterized B lymphoblast cell line which has been employed extensively in studies of mechanisms of leukemogenesis. The cell line is also a suitable transfection host
Storage Conditions liquid nitrogen vapor phase
Karyotype Male human karyotype with stemline number of 46. The karyotype is diploid in 66% of the cells and is stable within the stemline.
Derivation
The Daudi line was derived from a 16-year-old Black male with Burkitt's lymphoma by E. Klein and G. Klein in May, 1967. The cells are negative for beta-2-microglobulin. They are positive for EBNA, VCA and Surface immunoglobulin (sIg+). The line carries Epstein-Barr virus. ­
Clinical Data
16 years
Black
male
The Daudi line was derived from a 16-year-old Black male with Burkitt's lymphoma by E. Klein and G. Klein in May, 1967. The cells are negative for beta-2-microglobulin.
Receptor Expression
complement, expressed
Fc, expressed
Tumorigenic Yes
Comments
The Daudi line was derived from a 16-year-old Black male with Burkitt's lymphoma by E. Klein and G. Klein in May, 1967. The cells are negative for beta-2-microglobulin. They are positive for EBNA, VCA and Surface immunoglobulin (sIg+). The line carries Epstein-Barr virus. The Daudi is a well characterized B lymphoblast cell line which has been employed extensively in studies of mechanisms of leukemogenesis.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 3 to 5 X 10(5) viable cells/ml.
Interval: Maintain cell density between 3 X 10(5) and 2 to 3 X 10(6) viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Temperature: 37°C

Atmosphere: air, 95%; carbon dioxide (CO2), 5%
STR Profile
Amelogenin: X,Y
CSF1PO: 12
D13S317: 11,12
D16S539: 10,12
D5S818: 8,13
D7S820: 8,10
THO1: 6,7
TPOX: 8,11
vWA: 15,17
Isoenzymes
G6PD, B
Isotype IgM
Name of Depositor G Klein
Year of Origin May, 1967
References

Ohsugi Y, et al. Tumorigenicity of human malignant lymphoblasts: comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice, and X- irradiated nude mice. J. Natl. Cancer Inst. 65: 715-718, 1980. PubMed: 6932523

Klein E, et al. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res. 28: 1300-1310, 1968. PubMed: 4174339

Huber C, et al. Surface receptors on human haematopoietic cell lines. Clin. Exp. Immunol. 25: 367-378, 1976. PubMed: 963908

Nilsson K, et al. Tumorigenicity of human hematopoietic cell lines in athymic nude mice. Int. J. Cancer 19: 337-344, 1977. PubMed: 14896

Gao Y, et al. Induction of an exceptionally high-level, nontranslated, Epstein-Barr virus-encoded polyadenylated transcript in the uurkitts lymphoma line Daudi. J. Virol. 71: 84-94, 1997. PubMed: 8985326

Cuthbert JA, Lipsky PE. Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism. Cancer Res. 57: 3498-3504, 1997. PubMed: 9270019

Yamaguchi Y, et al. Biochemical characterization and intracellular localization of the Menkes disease protein. Proc. Natl. Acad. Sci. USA 93: 14030-14035, 1996. PubMed: 8943055

Lewis JA, et al. Inhibition of mitochondrial function by interferon. J. Biol. Chem. 271: 13184-13190, 1996. PubMed: 8662694

Montoya JG, et al. Human CD4+ and CD8+ T lymphocytes are both cytotoxic to Toxoplasma gondii-infected cells. Infect. Immun. 64: 176-181, 1996. PubMed: 8557337

Cross References

Nucleotide (GenBank) : U07990 Human Burkitt's lymphoma immunoglobulin kappa light chain mRNA, partial cds.

Nucleotide (GenBank) : U07987 Human Burkitt's lymphoma immunoglobulin IgM heavy chain Fd fragment mRNA, partial cds.

Basic Documentation
References

Ohsugi Y, et al. Tumorigenicity of human malignant lymphoblasts: comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice, and X- irradiated nude mice. J. Natl. Cancer Inst. 65: 715-718, 1980. PubMed: 6932523

Klein E, et al. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res. 28: 1300-1310, 1968. PubMed: 4174339

Huber C, et al. Surface receptors on human haematopoietic cell lines. Clin. Exp. Immunol. 25: 367-378, 1976. PubMed: 963908

Nilsson K, et al. Tumorigenicity of human hematopoietic cell lines in athymic nude mice. Int. J. Cancer 19: 337-344, 1977. PubMed: 14896

Gao Y, et al. Induction of an exceptionally high-level, nontranslated, Epstein-Barr virus-encoded polyadenylated transcript in the uurkitts lymphoma line Daudi. J. Virol. 71: 84-94, 1997. PubMed: 8985326

Cuthbert JA, Lipsky PE. Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism. Cancer Res. 57: 3498-3504, 1997. PubMed: 9270019

Yamaguchi Y, et al. Biochemical characterization and intracellular localization of the Menkes disease protein. Proc. Natl. Acad. Sci. USA 93: 14030-14035, 1996. PubMed: 8943055

Lewis JA, et al. Inhibition of mitochondrial function by interferon. J. Biol. Chem. 271: 13184-13190, 1996. PubMed: 8662694

Montoya JG, et al. Human CD4+ and CD8+ T lymphocytes are both cytotoxic to Toxoplasma gondii-infected cells. Infect. Immun. 64: 176-181, 1996. PubMed: 8557337